DMT210 Topical Gel in the Treatment of Atopic Dermatitis
NCT ID: NCT02949960
Last Updated: 2018-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
19 participants
INTERVENTIONAL
2016-10-31
2017-07-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis
NCT01993420
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
NCT03304470
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
NCT06024499
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
NCT02118792
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
NCT04212169
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DMT210 Topical Gel
DMT210 Topical Gel 5% applied to target lesion twice daily
DMT210 Topical Gel
DMT210 Topical Aqueous Gel 5% applied twice daily
Vehicle Control
Topical Gel vehicle applied to target lesion twice daily
Vehicle Control
Topical Vehicle Gel applied twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DMT210 Topical Gel
DMT210 Topical Aqueous Gel 5% applied twice daily
Vehicle Control
Topical Vehicle Gel applied twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement
* Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas
* Patient is willing and able to comply with the protocol
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dermata Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Nardo, PhD
Role: STUDY_DIRECTOR
Dermata Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermata Investigational Site
Houston, Texas, United States
Dermata Investigational Site
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMT210-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.